APOE4-Specific Proteolytic Fragment Inhibition Therapy

h-var-600b3e39aa

This therapeutic approach targets the pathogenic downstream consequence of APOE4's structural instability: the generation of neurotoxic C-terminal fragments through aberrant proteolytic cleavage. While APOE3 remains relatively stable due to its optimal lipidation state, APOE4's poorly lipidated form becomes highly susceptible to cleavage by thrombin, chymotrypsin, and other serine proteases at spe